CN1428146A - 一种含有曲马多的注射液及其应用 - Google Patents
一种含有曲马多的注射液及其应用 Download PDFInfo
- Publication number
- CN1428146A CN1428146A CN 01131691 CN01131691A CN1428146A CN 1428146 A CN1428146 A CN 1428146A CN 01131691 CN01131691 CN 01131691 CN 01131691 A CN01131691 A CN 01131691A CN 1428146 A CN1428146 A CN 1428146A
- Authority
- CN
- China
- Prior art keywords
- injection
- tramadol
- officinal salt
- promethazine
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 68
- 239000007924 injection Substances 0.000 title claims abstract description 68
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title claims abstract description 25
- 229960004380 tramadol Drugs 0.000 title claims abstract description 25
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 title claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000002904 solvent Substances 0.000 claims abstract description 16
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical group [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000008215 water for injection Substances 0.000 claims description 21
- 230000000202 analgesic effect Effects 0.000 claims description 20
- 235000010265 sodium sulphite Nutrition 0.000 claims description 18
- 229960003910 promethazine Drugs 0.000 claims description 17
- 230000003078 antioxidant effect Effects 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000003963 antioxidant agent Substances 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 4
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 abstract description 21
- 230000036407 pain Effects 0.000 abstract description 20
- 239000003814 drug Substances 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 25
- 229960003107 tramadol hydrochloride Drugs 0.000 description 25
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 19
- 229960002244 promethazine hydrochloride Drugs 0.000 description 19
- 238000000034 method Methods 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 239000003708 ampul Substances 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 4
- 239000000890 drug combination Substances 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- -1 inorganic acid salts Chemical class 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 206010058019 Cancer Pain Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229960005195 morphine hydrochloride Drugs 0.000 description 2
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940001482 sodium sulfite Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960005189 methadone hydrochloride Drugs 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 01131691 CN1204891C (zh) | 2001-12-27 | 2001-12-27 | 一种含有曲马多的注射液及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 01131691 CN1204891C (zh) | 2001-12-27 | 2001-12-27 | 一种含有曲马多的注射液及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1428146A true CN1428146A (zh) | 2003-07-09 |
CN1204891C CN1204891C (zh) | 2005-06-08 |
Family
ID=4670798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 01131691 Expired - Fee Related CN1204891C (zh) | 2001-12-27 | 2001-12-27 | 一种含有曲马多的注射液及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1204891C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100438863C (zh) * | 2004-08-17 | 2008-12-03 | 石药集团欧意药业有限公司 | 一种盐酸曲马多冻干粉针剂及其制备方法 |
RU2660356C2 (ru) * | 2012-04-30 | 2018-07-05 | Фармалидер, С.А. | Инъекционная фармацевтическая композиция декскетопрофена и трамадола |
-
2001
- 2001-12-27 CN CN 01131691 patent/CN1204891C/zh not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100438863C (zh) * | 2004-08-17 | 2008-12-03 | 石药集团欧意药业有限公司 | 一种盐酸曲马多冻干粉针剂及其制备方法 |
RU2660356C2 (ru) * | 2012-04-30 | 2018-07-05 | Фармалидер, С.А. | Инъекционная фармацевтическая композиция декскетопрофена и трамадола |
Also Published As
Publication number | Publication date |
---|---|
CN1204891C (zh) | 2005-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1686116A (zh) | 左旋奥硝唑的静脉给药制剂及其制备方法 | |
CN1368891A (zh) | 莫西沙星/氯化钠制剂 | |
CN101513387A (zh) | 埃索美拉唑镁注射液 | |
CN1879626A (zh) | 复合维生素b注射液及制备方法 | |
CN1565430A (zh) | 大蒜素环糊精包合物、制剂及制备方法 | |
CN1204891C (zh) | 一种含有曲马多的注射液及其应用 | |
CN1813739A (zh) | 一种注射用盐酸纳美芬冻干粉针制剂 | |
CN1085079C (zh) | 革宁息吐治疗手术后恶心呕吐的用途 | |
CN1897940A (zh) | 用于非经肠胃给药的长春氟宁医药组合物及其制备方法和用途 | |
CN1627950A (zh) | 用于治疗胃肠疾病的稳定药物组合物 | |
CN1429558A (zh) | 甘露聚糖肽注射液及其制备方法和使用方法 | |
CN101444479A (zh) | 一种拉帕替尼注射液及其制备方法 | |
CN1748758A (zh) | 血竭凝胶制剂及其制备方法 | |
CN1864666A (zh) | 甲磺酸左氧氟沙星冻干粉针注射剂及其制备方法 | |
CN1626081A (zh) | 注射用罗哌卡因冻干粉针剂及其制备方法 | |
CN1615867A (zh) | 注射用盐酸纳洛酮冻干粉针制剂 | |
CN1457780A (zh) | 植物来源总生物碱组合物及其药物制剂 | |
CN1939328A (zh) | 葛根素注射用制剂 | |
CN1843334A (zh) | 一种提高脂质体包封率的方法及其制剂 | |
CN1839842A (zh) | 一种含左西孟旦或其药学上可以接受的盐作为活性成分的药物组合物 | |
CN1830426A (zh) | 一种新鱼腥草素钠注射液及其制备方法和用途 | |
CN1733038A (zh) | 雪莲注射剂新的给药途径及其制备工艺 | |
CN1415301A (zh) | 含有苦参素、前列腺素e1和阿司匹林的复方制剂及其制备方法和用途 | |
CN1334725A (zh) | 普鲁泊福(2,6-二异丙基苯酚)和2,5-二-氧-甲基-1,4;3,6-双脱水-d-葡萄糖醇作为溶剂的胃肠外的溶液 | |
CN1287776C (zh) | 鱼腥草素钠注射剂的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING FATAI TIME MEDICINE TECHNOLOGY CO.LTD. Free format text: FORMER OWNER: SHENYANG PHARMACEUTICAL UNIVERSITY Effective date: 20071228 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20071228 Address after: Beijing City, Haidian District, three Tiger Bridge Bo apartment block A2 Room 305 Patentee after: Beijing Fatai Times Pharmaceutical Technology Co., Ltd. Address before: No. 103, Wenhua Road, Liaoning, Shenyang Patentee before: Shenyang Pharmaceutical University |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050608 Termination date: 20181227 |
|
CF01 | Termination of patent right due to non-payment of annual fee |